1
|
Gomez-Centeno A, Rubio-Romero E, Ovalles JG, Manrique-Arija S, Marsal-Barril S, Amarelo-Ramos J, del Pino-Montes J, Muñoz-Fernández S, Bustabad S, Barbazán-Álvarez C. Clinical and therapeutic management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: RADAR study. Rheumatol Int 2019; 39:2015-2024. [DOI: 10.1007/s00296-019-04378-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2019] [Accepted: 07/09/2019] [Indexed: 10/26/2022]
|
2
|
Mazzucchelli R, Pérez Fernandez E, Crespí-Villarías N, Quirós-Donate J, García Vadillo A, Espinosa M, Peña M, Macía-Villa C, Morell-Hita JL, Martinez-Prada C, Villaverde V, Morado Quiroga I, Guzón-Illescas O, Barbadillo C, Fernández Prada M, Godoy H, Herranz Varela A, Galindo Izquierdo M, Rodriguez Caravaca G. Trends in hip fracture in patients with rheumatoid arthritis: results from the Spanish National Inpatient Registry over a 17-year period (1999-2015). TREND-AR study. RMD Open 2018; 4:e000671. [PMID: 29955384 PMCID: PMC6018884 DOI: 10.1136/rmdopen-2018-000671] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2018] [Accepted: 05/08/2018] [Indexed: 12/23/2022] Open
Abstract
Purpose To analyse trends in hip fracture (HF) rates in patients with rheumatoid arthritis (RA) over an extended time period (17 years). Methods This observational retrospective survey was performed by reviewing data from the National Surveillance System for Hospital Data, which includes more than 98% of Spanish hospitals. All hospitalisations of patients with RA and HF that were reported from 1999 to 2015 were analysed. Codes were selected using the Ninth International Classification of Diseases, Clinical Modification: ICD-9-CM: RA 714.0 to 714.9 and HF 820.0 to 820.3. The crude and age-adjusted incidence rate of HF was calculated by age and sex strata over the last 17 years. General lineal models were used to analyse trends. Results Between 1999 and 2015, 6656 HFs occurred in patients with RA of all ages (84.25% women, mean age 77.5 and 15.75% men, mean age 76.37). The age-adjusted osteoporotic HF rate was 221.85/100 000 RA persons/ year (women 227.97; men 179.06). The HF incidence rate increased yearly by 3.1% (95% CI 2.1 to 4.0) during the 1999–2015 period (p<0.001) and was more pronounced in men (3.5% (95% CI 2.1 to 4.9)) than in women (3.1% (95% CI 2.3 to 4.1)). The female to male ratio decreased from 1.54 in 1999 to 1.14 in 2015. The average length of hospital stays (ALHS) decreased (p<0.001) from 16.76 days (SD 15.3) in 1999 to 10.78 days (SD 7.72) in 2015. Age at the time of hospitalisation increased (p<0.001) from 75.3 years (SD 9.33) in 1999 to 79.92 years (SD 9.47) in 2015. There was a total of 326 (4.9%) deaths during admission, 247 (4.4%) in women and 79 (7.5%) in men (p<0.001). Conclusion In Spain, despite the advances that have taken place in controlling disease activity and in treating osteoporosis, the incidence rate of HF increased in both male and female patients with RA.
Collapse
Affiliation(s)
- Ramón Mazzucchelli
- Department of Rheumatology, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - Elia Pérez Fernandez
- Department of Clinical Research, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | | | - Javier Quirós-Donate
- Department of Rheumatology, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | | | - María Espinosa
- Department of Rheumatology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
| | - Marina Peña
- Department of Rehabilitation, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | | | | | | | - Virginia Villaverde
- Department of Rheumatology, Hospital Universitario de Móstoles, Madrid, Spain
| | | | - Olalla Guzón-Illescas
- Department of Rehabilitation, Hospital Universitario Fundación Alcorcón, Madrid, Spain
| | - Carmen Barbadillo
- Department of Rheumatology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
| | | | - Hilda Godoy
- Department of Rheumatology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain
| | | | | | - Gil Rodriguez Caravaca
- Department of Preventive Medicine and Public Health, Universidad Rey Juan Carlos I, Madrid, Spain
| |
Collapse
|
3
|
Seoane IV, Martínez C, García-Vicuña R, Ortiz AM, Juarranz Y, Talayero VC, González-Álvaro I, Gomariz RP, Lamana A. Vasoactive intestinal peptide gene polymorphisms, associated with its serum levels, predict treatment requirements in early rheumatoid arthritis. Sci Rep 2018; 8:2035. [PMID: 29391448 PMCID: PMC5794878 DOI: 10.1038/s41598-018-20400-6] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2017] [Accepted: 01/12/2018] [Indexed: 12/14/2022] Open
Abstract
We previously reported that early arthritis (EA) patients with low vasoactive intestinal peptide (VIP) serum levels demonstrate a worse clinical disease course. In this study, we analysed whether variants in the VIP gene correlated with its serum levels and clinical EA parameters. The VIP gene was sequenced in patients with extremely high/low VIP levels, measured by enzyme immunoassay. Sixteen single nucleotide polymorphisms (SNPs) were differentially distributed between both groups, which were subsequently genotyped in two patients’ sets. We observed that patients with rs688136 CC genotype showed higher VIP levels in both discovery (n = 91; p = 0.033) and validation populations (n = 131; p = 0.007). This effect was attenuated by the presence of minor alleles rs35643203 and rs12201140, which showed a clear trend towards low VIP level association (p = 0.118 and p = 0.049, respectively). Functional studies with miR-205-5p, which has a target site in the 3′ UTR close to rs688136, revealed a miRNA-mediated regulatory mechanism explaining the higher VIP gene expression in homozygous patients. Moreover, patients with an rs688136 CC genotype and no minor alleles of the other polymorphisms required less treatment (p = 0.009). We concluded that the identification of polymorphisms associated with VIP serum levels would complement the clinical assessment of the disease severity in rheumatoid arthritis patients.
Collapse
Affiliation(s)
- Iria V Seoane
- Departamento de Biología Celular, Facultad de Biología, Universidad Complutense de Madrid, Madrid, 28040, Spain
| | - Carmen Martínez
- Departamento de Biología Celular, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, 28040, Spain
| | - Rosario García-Vicuña
- Servicio de Reumatología, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria la Princesa, 28006, Madrid, Spain
| | - Ana M Ortiz
- Servicio de Reumatología, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria la Princesa, 28006, Madrid, Spain
| | - Yasmina Juarranz
- Departamento de Biología Celular, Facultad de Biología, Universidad Complutense de Madrid, Madrid, 28040, Spain
| | - Vanessa C Talayero
- Servicio de Reumatología, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria la Princesa, 28006, Madrid, Spain
| | - Isidoro González-Álvaro
- Servicio de Reumatología, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria la Princesa, 28006, Madrid, Spain
| | - Rosa P Gomariz
- Departamento de Biología Celular, Facultad de Biología, Universidad Complutense de Madrid, Madrid, 28040, Spain.
| | - Amalia Lamana
- Servicio de Reumatología, Hospital Universitario de la Princesa, Instituto de Investigación Sanitaria la Princesa, 28006, Madrid, Spain
| |
Collapse
|
4
|
Lopez-Gonzalez R, Seoane-Mato D, Perez-Vicente S, Martin-Martinez MA, Sanchez-Alonso F, Silva-Fernandez L. Variability in the frequency of rheumatology consultations in patients with rheumatoid arthritis in Spain. Rheumatol Int 2016; 36:1525-1534. [PMID: 27538838 DOI: 10.1007/s00296-016-3547-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2016] [Accepted: 08/02/2016] [Indexed: 11/30/2022]
Abstract
The aim of this work was to assess the variability in the use of health-care resources, based on the number of visits to rheumatology departments by rheumatoid arthritis patients, in Spain, and its association with patient, physician and center characteristics. The sample consisted of patient records of men and women (aged 16 or older), with a clinical diagnosis of RA, who met the American Rheumatism Association 1987 revised criteria and who had been treated in a rheumatology department at a Spanish hospital with at least one visit to a rheumatologist during the two years preceding the date of the study. To analyze which variables were independently associated with the number of consultations, those with a statistically significant result in the bivariate analysis, or which were clinically relevant or deemed confounders, were used in the construction of a linear regression model. The records of 1188 RA patients were studied. The linear regression model explained the 26.67 % of the variability in the number of visits. The number of csDMARDs prescribed, the administration of biological therapy, corticoid prescription, the presence of nursing consultation, mean time to first visit in the department and attended population showed a positive significant association, while the presence of telephone consultation, distance from the hospital to the patient´s residence (≥20 km) and drug monitoring by rheumatology department + primary care physician or by other specialists were negatively associated with the number of consultations. We observed a high variability in the number of visits, which remains partially unexplained even after taking into account individual, physician and center characteristics.
Collapse
Affiliation(s)
- R Lopez-Gonzalez
- Rheumatology Unit, Rheumatology Department, Complejo Hospitalario de Zamora, Avenida Requejo 35, 49022, Zamora, Spain.
| | - D Seoane-Mato
- Research Unit, Spanish Society of Rheumatology, Madrid, Spain
| | - S Perez-Vicente
- Research Unit, Spanish Society of Rheumatology, Madrid, Spain
| | | | | | - L Silva-Fernandez
- Rheumatology Department, Complexo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, Spain
| | | |
Collapse
|
5
|
González-Álvaro I, Ortiz AM, Seoane IV, García-Vicuña R, Martínez C, Gomariz RP. Biomarkers predicting a need for intensive treatment in patients with early arthritis. Curr Pharm Des 2015; 21:170-81. [PMID: 25163741 PMCID: PMC4298237 DOI: 10.2174/1381612820666140825123104] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2014] [Accepted: 08/13/2014] [Indexed: 12/29/2022]
Abstract
The heterogeneous nature of rheumatoid arthritis (RA) complicates early recognition and treatment. In recent years, a growing body of evidence has demonstrated that intervention during the window of opportunity can improve the response to treatment and slow—or even stop—irreversible structural changes. Advances in therapy, such as biologic agents, and changing approaches to the disease, such as the treat to target and tight control strategies, have led to better outcomes resulting from personalized treatment to patients with different prognostic markers. The various biomarkers identified either facilitate early diagnosis or make it possible to adjust management to disease activity or poor outcomes. However, no single biomarker can bridge the gap between disease onset and prescription of the first DMARD, and traditional biomarkers do not identify all patients requiring early aggressive treatment. Furthermore, the outcomes of early arthritis cohorts are largely biased by the treatment prescribed to patients; therefore, new challenges arise in the search for prognostic biomarkers. Herein, we discuss the value of traditional and new biomarkers and suggest the need for intensive treatment as a new surrogate marker of poor prognosis that can guide therapeutic decisions in the early stages of RA.
Collapse
Affiliation(s)
| | | | | | | | | | - R P Gomariz
- Rheumatology Service, Hospital Universitario de La Princesa, IIS Princesa, Madrid, Spain.
| |
Collapse
|
6
|
Ibañez M, Ortiz AM, Castrejón I, García-Vadillo JA, Carvajal I, Castañeda S, González-Alvaro I. A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone mass. Arthritis Res Ther 2010; 12:R50. [PMID: 20331862 PMCID: PMC2888199 DOI: 10.1186/ar2961] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2009] [Revised: 11/20/2009] [Accepted: 03/23/2010] [Indexed: 01/01/2023] Open
Abstract
Introduction Glucocorticoid (GC)-induced osteoporosis is a frequent complication in patients with rheumatoid arthritis. However, little information exists about the consequences of GC use in patients with early arthritis. Here we describe the variables underlying the use of GC in early arthritis, as well as its effect on bone-mineral density. Methods Data from 116 patients in our early arthritis register were analyzed (90 women; median age, 52.5 years, interquartile range (IQR, 38.5-66); 6-month median disease duration at entry (IQR, 4-9)). In this register, the clinical and treatment information was recorded systematically, including the cumulative GC dose. Lumbar spine, hip, and forearm bone-mineral density (BMD) measurements were performed at entry and after a 2-year follow-up. A multivariate analysis was performed to establish the variables associated with the use of GCs, as well as those associated with variations in BMD. Results Of the patients with early arthritis studied, 67% received GCs during the 2-year follow-up. GCs were more frequently prescribed to elderly patients, those with higher basal disease activity and disability, and patients with positive rheumatoid factor. When adjusted for these variables, GCs were less frequently prescribed to female patients. The use of GCs was associated with an increase of BMD in the ultradistal region of the forearm, although it induced a significant loss of BMD in the medial region of the forearm. No relevant effect of GC was noted on the BMD measured at other locations. Conclusions The frequent use of GCs as a "bridge therapy" in patients with early arthritis does not seem to be associated with relevant loss of bone mass. Moreover, cumulative GC administration might be associated with an increase of juxtaarticular BMD.
Collapse
Affiliation(s)
- Monica Ibañez
- Rheumatology Department, Hospital Son Llàtzer, Carretera Manacor km, 4, Palma de Mallorca, 07198, Spain
| | | | | | | | | | | | | |
Collapse
|
7
|
[Variations in clinical practice. Current status and challenges for nursing]. ENFERMERIA CLINICA 2010; 20:114-8. [PMID: 20189858 DOI: 10.1016/j.enfcli.2009.12.004] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2009] [Revised: 11/30/2009] [Accepted: 12/10/2009] [Indexed: 11/21/2022]
Abstract
The clinical practice can vary in every step of the process. The following article provides an overview of the most important concepts in the study of variations in clinical practice and the status of nursing regarding these variations. The variability can be seen both from a population and an individual point of view. These variations in practice have problems with quality of care and show that the practice is poorly based in research. The uncertainty hypothesis is the most cited as a primary cause of variations and leads to a style of practice by health professionals to use procedures which have ambiguous incomplete evidence. The main actions to address variations should focus on unwarranted variations and should be developed at institutional level. Most variability studies have been performed from the physician perspective and much less has been done from a nursing one. Paradoxically, few studies have described the level of variability in nursing, however, there are more studies on clinical practice guidelines, clinical pathways and protocols that attempt to standardise practice. Variability is therefore a phenomenon that is presumed to exist, but in many cases is unknown.
Collapse
|
8
|
Lopez‐Gonzalez R, Hernandez‐Garcia C, Abasolo L, Morado I, Lajas C, Vadillo C, Pato E, Fernandez‐Gutierrez B, Jover JA, Loza E, the emAR Study Group. Differences between rheumatology attending physicians and training residents in the management of rheumatoid arthritis in Spain. Scand J Rheumatol 2009; 37:419-26. [DOI: 10.1080/03009740802055992] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
9
|
González-Alvaro I, Descalzo MA, Carmona L. Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohort. Arthritis Res Ther 2008; 10:R138. [PMID: 19036152 PMCID: PMC2656242 DOI: 10.1186/ar2561] [Citation(s) in RCA: 31] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/03/2008] [Revised: 10/02/2008] [Accepted: 11/26/2008] [Indexed: 11/10/2022] Open
Abstract
INTRODUCTION The disease activity in patients with rheumatoid arthritis has improved during the past decade. The availability of new drugs and also a better assessment of the disease have been proposed to be responsible for this improvement. In the present work we estimate the effect of these factors on disease activity and function in patients with rheumatoid arthritis at the beginning of the new century. METHODS The Estudio de la Morbilidad y Expresión Clínica de la Artritis Reumatoide (EMECAR) cohort was assembled in 2000 from the random sampling of rheumatoid arthritis patients registered in 34 centers. The cohort was composed of 789 patients who underwent a baseline assessment plus four annual follow-up visits in which functional ability (Health Assessment Questionnaire score), the disease activity score obtained from 28-joint count with three parameters (DAS28-3) and radiological progression (Larsen score) were recorded. The effect of the calendar year on the DAS28-3, the Health Assessment Questionnaire score, and the Larsen score was obtained from adjusted models in which all treatments were included as dummy variables. RESULTS The effect of time as the beta coefficient (95% confidence interval) for 2004, taking 2000 as a reference year, was -0.43 (-0.58 to -0.28) for the DAS28-3, 0.15 (0.07 to 0.22) for the Health Assessment Questionnaire score, and 4.4 (2.68 to 6.12) for the Larsen score. Treatment with new therapies, either leflunomide or TNF antagonists, increased in frequency from 1.1% (n = 8) in 2000 to 30.9% (n = 144) in 2004. Treatment with TNF antagonists (-0.28 (-0.5 to -0.05)) and with gold salts (-0.21 (-0.38 to -0.04)) was independently associated with a decrease in the DAS28-3 over time, whereas cyclosporin A treatment (0.45 (0.13 to 0.76)) was associated with an increase in disease activity. CONCLUSIONS The mean disease activity of rheumatoid arthritis has improved from 2000 to 2004. An explanation is the introduction of new therapies, but not solely. Other factors related to the calendar year, plausibly a better management of available drugs, show a greater effect on improvement than the drugs used.
Collapse
|
10
|
Carbonell J, Cobo T, Balsa A, Descalzo MA, Carmona L. The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. Rheumatology (Oxford) 2008; 47:1088-92. [PMID: 18511475 DOI: 10.1093/rheumatology/ken205] [Citation(s) in RCA: 68] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- J Carbonell
- Rheumatology Department, Hospital del Mar, Institut Municipal Atencio Sanitaria, Barcelona
| | | | | | | | | |
Collapse
|
11
|
Clemente D, Hernández-García C, Abásolo L, Villaverde V, Lajas C, Loza E, López-González R, Vadillo C, Fernández-Gutiérrez B, Morado I, Angel Jover J. Disminución del tiempo hasta el primer tratamiento con fármacos modificadores de la enfermedad en pacientes con artritis reumatoide. ACTA ACUST UNITED AC 2007; 3:245-50. [PMID: 21794441 DOI: 10.1016/s1699-258x(07)73698-7] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2007] [Accepted: 09/13/2007] [Indexed: 11/28/2022]
Affiliation(s)
- Daniel Clemente
- Servicio de Reumatología. Hospital Clínico San Carlos. Madrid. España
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|